Leveragen Inc., a Boston-based biotechnology company specializing in next-generation genetic models for antibody discovery, ...

SARS-CoV-2 is a positive-sense single-stranded RNA virus. It is contagious in humans and is the cause of the coronavirus disease 2019 (COVID-19). A SARS-CoV-2 antibody, NT-108, exhibits potent ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell ...

Developed by Sanofi, CABLIVI is the first FDA-approved nanobody therapy for this condition. Increasing awareness, improved diagnostic rates, and rising demand for targeted therapies in hematology ...

DelveInsight's "CABLIVI Market Size, Forecast, and Market Insight Report" highlights the details around CABLIVI, a von ...

AstraZeneca’s EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases.

British-Swedish multinational pharmaceutical and biotechnology company AstraZenica on Monday announced the acquisition of ...

AstraZeneca makes a deal to buy another biotech company, this one with a price tag that could reach $1 billion.

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...

EsoBiotec develops therapies that engineer immune cells within the body, eliminating the need for patients to go through lymphodepletion and reinfusion.

The UK drugmaker AstraZeneca has agreed to acquire Belgian cell therapy developer EsoBiotec for up to $1bn to enhance its cancer treatment capabilities. Read more.

AstraZeneca, headquartered in Cambridge, could pay up to $1 billion on a cash and debt-free basis for Belgian company ...